  Development of the next generations of cancer therapy modalities is currently
a crucial requirement of oncology. Advances in nanotechnology are bringing us
closer to the development of dual and multifunctional nanoparticles that are
challenging the traditional distinction between diagnostic and treatment
agents. The chase of innovative, multifunctional, more efficient, and safer
treatments is a major challenge in preclinical nanoparticle-mediated
thermotherapeutic research for breast cancer. Here, we report that iron oxide
nanoparticles have the dual capacity to act as both magnetic and drug delivery
agents. The aim of this work was to investigate the in vitro effect of the
loading of doxorubicin (DOX) on negatively charged polycarboxylic iron-oxide
nanoparticles (SPIONs) and Rhodamine B functionalized SPIONs on breast
carcinoma cell lines. For proper analysis and understanding of cell behavior
after administration of DOX-SPIONs compared with free DOX, a complex set of in
vitro tests, including production of MTT assay, cell cycle determination, and
cellular uptake, were utilized. In summary, we have developed a magnetic
nanoparticle-based drug delivery system that sequentially delivers the
cytotoxic drug doxorubicin to breast cancer cells (MCF-7 and MDA-MB-231). The
drug-coated nanoparticles, DOX-NPs, were assembled stepwise, with doxorubicin
adsorbed to bare iron oxide nanoparticles first, by electrostatic reaction and
allowed for the complexation of doxorubicin. In contrast, they were
internalized to a much greater extent in MCF-7 and MDA-MB-231 cells and were
cytotoxic due to the synergistic action of the two drugs and the effects of
hyperthermia. The drug-coated particles were able to inhibit growth and
proliferation of breast cancer cells in vitro, indicating that the system has
potential to act as an antimetastatic chemothermotherapeutic agent.
